4587.T
PeptiDream Inc. [4587.T] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
4587.T Stock Summary
In the News
4587.T Financial details
Company Rating
-
Market Cap
200.5B
Income
3.04B
Revenue
28.71B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
603
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
16.44
Forward P/E
-
PEG
-2.75
P/S
4.86
P/B
4.95
P/C
-
P/FCF
20.13
Quick Ratio
2.13
Current Ratio
2.4
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
23.43
EPS next Y
-
EPS next Q
-
EPS this Y
-59.77%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
69.13%
Revenue Q/Q
-52.98%
EPS Q/Q
-111.84%
-
-
-
-
SMA20
0.43%
SMA50
0.73%
SMA100
-2.08%
Inst Own
-
Inst Trans
-
ROA
17%
ROE
34%
ROC
0.3%
Gross Margin
70%
Oper. Margin
42%
Profit Margin
30%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1039.0-2549.0
52W High
-35.01%
52W Low
+59.43%
RSI
53
Rel Volume
0.94
Avg Volume
828.46K
Volume
774.8K
Perf Week
0.73%
Perf Month
-0.33%
Perf Quarter
8.16%
Perf Half Y
2.1%
-
-
-
-
Beta
0.755
-
-
Volatility
18.41%, 62.49%
Prev Close
0%
Price
1656.5
Change
-2.39%
Company Profile
- Volume Average 828.46K
- Market Capitalization 200.5B
- Employee 603
- CEO Dr. Patrick Crawford Reid Ph.D.
- Headquarters Kawasaki,JP
- IPO Date 2013-06-12
-
Website
https://www.peptidream.com 
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform for the development of peptides. It has a collaborative research and exclusive license agreement with Takeda Pharmaceutical Company Limited to develop peptide drug conjugates for neuromuscular diseases. The company was incorporated in 2006 and is headquartered in Kawasaki, Japan.
